• OPEN AN ACCOUNT
Indian Indices
Sensex
78,005.08 438.92
( 0.57%)
Global Indices
Nasdaq
47,737.88 215.33
(0.45%)
Dow Jones
6,814.47 53.45
(0.79%)
Hang Seng
52,808.52 -2,812.32
(-5.06%)
Nikkei 225
10,249.54 -35.21
(-0.34%)
Forex
USD-INR
91.85 0.10
(0.11%)
EUR-INR
106.60 0.13
(0.12%)
GBP-INR
123.04 0.62
(0.51%)
JPY-INR
0.58 0.00
(-0.25%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

nalwa sons investments ltd
Dr Reddy's Lab gets EIR from USFDA for Srikakulam facility
Mar 06,2026
The USFDA classified the inspection outcome as “Voluntary Action Indicated” (VAI) and confirmed that the inspection has been officially closed under 21 CFR 20.64(d)(3).

The inspection included both a Good Manufacturing Practice (GMP) review and a Pre-Approval Inspection (PAI) conducted at the company’s FTO-SEZ PU01 facility. The company had earlier informed about the USFDA inspection on 12 December 2025.

Hyderabad-based Dr Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

Dr Reddy’s Laboratories reported a 14.4% decline in consolidated net profit to Rs 1,209.8 crore despite a 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25.

The counter shed 0.91% to Rs 1,301.10 on the BSE.